Welcome back to Endpoints Weekly, our roundup of the top headlines in biopharma. Earnings season continued this week, with more comments from pharma executives on the potential impact of tariffs ...

Ver­tex is pulling back on its ge­net­ic med­i­cine re­search, end­ing all work re­lat­ed to ade­no-as­so­ci­at­ed virus­es, ...

Flagship Pioneering has recruited Rahul Kakkar to lead its genetics-based drug discovery startup Quotient Therapeutics.

The White House’s budget request proposes a nearly $18 billion cut to NIH spending, and nearly $4 billion slashed at the CDC.

Pathos AI, a Chicago biotech led by executives of the healthcare AI group Tempus, is looking at a funding round of up to $400 ...

When Siren Biotechnology CEO Nicole Paulk learned last month that top FDA official Peter Marks had resigned, she began ...

Aviva Capital Partners & Socius plan £1B cancer research hub in Sutton, UK, near Institute of Cancer Research & Royal Marsden ...

FDA delays Cytokinetics' aficamten PDUFA date to Dec 26 after company adds REMS to heart disease drug application; stock down ...

Moderna is expanding a cost control program as it seeks to break even in the coming years, despite challenges for vaccine ...

While Pfizer recently pulled the plug on its most advanced obesity candidate, Amgen has moved its own key weight loss play ...

Bristol Myers Squibb closing viral vector site in Libertyville, IL, shifting production to Devens, MA; affects workers from ...

Amicus pays Dimerix $30M upfront for US rights to DMX-200, a late-stage FSGS therapy, with potential milestone payments of ...